Optimal Stack Recommendation: IGF-1 DES + HGH as the Preferred Combined Protocol
The speaker's concluding recommendation is to combine IGF-1 DES with HGH as the optimal stacking strategy, allowing users to benefit from both exogenous IGF-1 activity (via DES) and the full systemic benefits of HGH (recovery, sleep, fat loss, endogenous IGF-1 production). This combination is presented as superior to using IGF-1 LR3 with HGH. The recommendation is based on the speaker's applied pharmacokinetic reasoning and coaching experience.
IGF-1 DES Short Half-Life Prevents Receptor Desensitization — Key Safety Advantage Over LR3
The speaker contrasts IGF-1 DES with IGF-1 LR3 by emphasizing that DES's short half-life allows it to be cleared from the system before receptor desensitization can occur. This pharmacokinetic property is identified as the primary safety and efficacy advantage of DES over LR3. The speaker frames this as the mechanism by which DES delivers IGF-1 benefits without the associated receptor downregulation risk.
IGF-1 DES Protocol: Intramuscular Pre-Workout Injection Into Target Muscle
The speaker describes a specific administration protocol for IGF-1 DES: it should be injected intramuscularly into the specific muscle being trained, and administered pre-workout. The localized injection approach is implied to concentrate IGF-1 activity in the target muscle. No specific dosage in mcg is provided in this transcript.
IGF-1 DES Recommended as the Preferred IGF-1 Variant When Stacking With HGH
The speaker recommends IGF-1 DES (des(1-3)IGF-1) as the appropriate IGF-1 variant to use alongside HGH, specifically because its short half-life prevents receptor desensitization. This is presented as the correct stacking strategy when additional IGF-1 activity beyond endogenous production is desired. The recommendation is based on pharmacokinetic reasoning rather than cited clinical data.